Markets:

Overview

News

Currencies

International

Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

33.49 +0.34 (+1.04%)

Streaming Delayed Price Updated: 10:45 AM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

April 16, 2026

Via Chartmill

Veracyte Inc (NASDAQ:VCYT) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗

April 02, 2026

Via Chartmill

Veracyte Names Kevin Haas as Chief Development and Technology Officer

March 16, 2026

From Veracyte, Inc.

Via Business Wire

Veracyte (VCYT) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Veracyte (VCYT) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Veracyte Inc (NASDAQ:VCYT) Posts Strong Q4 Earnings Beat and Positive 2026 Outlook ↗

February 25, 2026

Via Chartmill

Topics Earnings

Veracyte Inc (NASDAQ:VCYT): A Prime GARP Stock with Strong Growth and a Sound Balance Sheet ↗

February 21, 2026

Via Chartmill

Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate ↗

January 26, 2026

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results

February 25, 2026

From Veracyte, Inc.

Via Business Wire

Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

February 24, 2026

From Veracyte

Via Business Wire

Veracyte to Participate in Upcoming Investor Conferences

February 19, 2026

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

February 04, 2026

From Veracyte, Inc.

Via Business Wire

Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability

January 12, 2026

On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025...

Via MarketMinute

Topics Artificial Intelligence Death

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

January 11, 2026

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Inc (NASDAQ:VCYT) Emerges as a Top Affordable Growth Stock ↗

December 25, 2025

Veracyte (VCYT) exemplifies the GARP strategy, offering strong growth, a reasonable industry price, and a solid debt-free financial foundation.

Via Chartmill

Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price ↗

December 02, 2025

Veracyte (VCYT) exemplifies GARP investing with strong cancer diagnostic growth, reasonable valuation vs. biotech peers, and a debt-free financial foundation.

Via Chartmill

Veracyte to Participate in Upcoming Investor Conferences

November 06, 2025

From Veracyte, Inc.

Via Business Wire

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗

November 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Veracyte Announces Third Quarter 2025 Financial Results

November 04, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech ↗

October 30, 2025

Veracyte (VCYT) offers affordable growth with strong earnings, a solid balance sheet, and reasonable valuation in the biotech sector.

Via Chartmill

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

October 15, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

November 03, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity ↗

October 14, 2025

Veracyte (VCYT) stock analysis shows strong growth potential with 20% revenue growth, zero debt, and a bullish technical setup for a breakout.

Via Chartmill

Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Cancer Diagnostics ↗

October 08, 2025

Veracyte (VCYT) offers affordable growth with strong revenue & earnings expansion, a solid debt-free balance sheet, and reasonable valuation for the biotech sector.

Via Chartmill

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

September 28, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

September 24, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

September 09, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 29, 2025

From Veracyte, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.